Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients

Diseases of the Esophagus

Volumn 21, Issue 8, 2008, Pages 679-684

  Huang, W Z ^a,b   Fu, J H ^a,b   Wang, D K ^b   Hu, Y ^a,b   Liu, M Z ^a,b   Yang, H ^a,b   Feng, Y F ^a,b   Zheng, B ^a,b   Wang, G ^a,b   Luo, K J ^a,b   Wen, J ^a,b   Rong, T H ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemoradiotherapy; Cyclooxygenase 2; Esophageal neoplasm; Prognosis

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYCLOOXYGENASE 2; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 56349123152     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2008.00824.x     Document Type: Article

References (27)

1. Brucher B L, Stein H J, Zimmermann F et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 2004; 30: 963-71.
2. Berger A C, Farma J, Scott W J et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-7.
3. Gaffney D K, Holden J, Davis M, Zempolich K, Murphy K J, Dodson M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49: 1213-7.
4. Ferrandina G, Lauriola L, Zannoni G F et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002; 13: 1205-11.
5. Kim Y B, Kim G E, Cho N H et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002; 95: 531-9.
6. Wulfing C, Eltze E, von Struensee D, Wulfing P, Hertle L, Piechota H. Cyclooxygenase-2 expression in bladder cancer: Correlation with poor outcome after chemotherapy. Eur Urol 2004; 45: 46-52.
7. Milas L, Kishi K, Hunter N, Mason K, Masferrer J L, Tofilon P J. Enhancement of tumour response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 1999; 91: 1501-4.
8. Pyo H, Choy H, Amorino G P et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001; 7: 2998-3005.
9. Trifan O C, Durham W F, Salazar V S et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62: 5778-84.
10. Petersen C, Petersen S, Milas L, Lang F F, Tofilon P J. Enhancement of intrinsic tumour cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000; 6: 2513-20.
11. Zimmermann K C, Sarbia M, Weber A A, Borchard F, Gabbert H E, Schror K. Cyclooxygenase-2 experssion in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
12. Williams C S, Mann M, DuBois R N. The role of cyclooxygenase in inflammation, cancer and development. Oncogene 1999; 18: 7908-16.
13. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999; 1438: 120-30.
14. DuBois R N, Tsujii M, Bishop P, Awad J A, Makita K, Lanahan A. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol 1994; 266 (5 Pt 1): G822-7.
15. Jones D A, Carlton D P, McIntyre T M, Zimmerman G A, Prescott S M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 9049-54.
16. Sano H, Kawahito Y, Wilder R L et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-9.
17. Buskens C J, Van Rees B P, Sivula A et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122: 1800-7.
18. Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-4.
19. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-80.
20. Uchida K, Schneider S, Yochim J M et al. Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2005; 11: 3363-8.
21. Ferrandina G, Lauriola L, Zannoni G F et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002; 13: 1205-11.
22. Nix P, Lind M, Greenman J, Stafford N, Cawkwell L. Expression of Cox-2 protein in radioresistant laryngeal cancer. Ann Oncol 2004; 5: 797-801.
23. Takatori H, Natsugoe S, Okumura H et al. Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncol Rep 2005; 13: 697-701.
24. Kulke M H, Odze R D, Mueller J D, Wang H, Redston M, Bertagnolli M M. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg 2004; 127: 1579-86.
25. Kawabe A, Shimada Y, Uchida S et al. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology 2002; 62: 46-54.
26. Shamma A, Yamamoto H, Doki Y et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 2000; 6: 1229-38.
27. Sivula A, Buskens C J, van Rees B P et al. Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int J Cancer 2005; 116: 903-8.